Xenon Pharmaceuticals Inc (NASDAQ:XENE) shares, rose in value on Friday, June 20, with the stock price up by 0.47% to the previous day’s close as strong demand from buyers drove the stock to $32.05.
Actively observing the price movement in the last trading, the stock closed the session at $31.90, falling within a range of $31.68 and $32.72. The value of beta (5-year monthly) was 1.097. Referring to stock’s 52-week performance, its high was $46.00, and the low was $26.74. On the whole, XENE has fluctuated by 1.97% over the past month.
With the market capitalization of Xenon Pharmaceuticals Inc currently standing at about $2.46 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that XENE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of XENE currently trading nearly 3.59% and -2.88% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 51.34, while the 7-day volatility ratio is showing 1.37% which for the 30-day chart, stands at 1.89%. Furthermore, Xenon Pharmaceuticals Inc (XENE)’s beta value is 1.10, and its average true range (ATR) is 1.38.
A comparison of Xenon Pharmaceuticals Inc (XENE) with its peers suggests the former has fared considerably weaker in the market. XENE showed an intraday change of 0.47% in last session, and over the past year, it shrunk by -12.43%%.
Data on historical trading for Xenon Pharmaceuticals Inc (NASDAQ:XENE) indicates that the trading volumes over the past 10 days have averaged 0.73 and over the past 3 months, they’ve averaged 1.01 million. According to company’s latest data on outstanding shares, there are 76.59 million shares outstanding.
Nearly 3.05% of Xenon Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 97.49% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.37 million shares as on 2025-05-30, resulting in a short ratio of 2.34. According to the data, the short interest in Xenon Pharmaceuticals Inc (XENE) stood at 489.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 3.58 million. The stock has fallen by -18.24% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the XENE stock heading into the next quarter.
